Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accrual, affinity, antitumor, avidity, bacterial, began, binding, block, body, CA, carboplatin, cease, chart, Conference, cooperative, death, decide, demonstrated, differentiate, differentiated, discontinuation, discontinuing, disease, doublet, efficacy, endothelial, endpoint, enhance, European, exceed, facilitate, FL, Florida, fold, fourth, free, group, heading, headquarter, healthy, higher, independent, investigated, investigator, invonescimab, irrevocable, joined, knowledge, larger, letter, Licensee, Litigation, mechanism, met, Miami, microenvironment, modify, mOS, mutual, North, optimal, owe, paclitaxel, pemetrexed, percentage, platform, population, precision, predetermined, profile, propensity, protein, published, Reform, Royalty, sensitivity, separate, shown, side, solid, sponsored, sponsoring, stage, strength, structure, suite, supplier, Tetrabody, tetravalent, tied, tissue, TME, tolerable, undiscounted, unique, unrecognized, unvested, varying, vascular, VEGF, vesting, view, vitro
Removed:
acceptance, Additionally, advance, American, annum, anticipating, apply, arrangement, ASC, Assistant, ASU, attributed, authoritative, authorized, awarded, beginning, Biomedical, brought, call, Cambridge, Certified, clarification, close, committed, concluding, consistency, consulting, consummate, consummation, Corporation, customer, deferred, degree, Department, diversity, divestiture, earlier, Ending, expiration, FASB, forward, freestanding, geographical, Hedging, immaterial, Institute, issuer, laboratory, light, loaned, Mahkam, manufacture, modification, multiregional, occurred, open, ordinary, oversubscribed, partnership, path, prospective, ran, randomized, ratably, reclassification, reclassified, reduced, reducing, register, registered, registration, resale, retroactively, reviewed, Robert, Secretary, state, Subtopic, technical, Topic, utility, worth
Financial report summary
?Management Discussion
- Amounts reported in millions within this Quarterly Report are computed based on the amounts in thousands, and therefore, the sum of components may not equal the total amount reported in millions due to rounding.
- The table below summarizes our research and development expenses by category for the three month periods ended March 31, 2024 and 2023, respectively.
- The entry into the License Agreement with Akeso, Inc., effective in January 2023, represents a significant change in our strategy from anti-infectives to the therapeutic area of oncology.